Partial-onset Seizures With or Without Secondary Generalisation
Conditions
Brief summary
A dose randomized, double-blind, placebo controlled, single and multiple dosing, dose-escalation phase I clinical trial to investigate the safety, tolerability and pharmacokinetic characteristics of Zebinix (Eslicarbazepine acetate) after oral administration in healthy Korean and Caucasian adult subjects
Interventions
DRUGZebinix 400mg
Zebinix 400mg group is administered with two Zebinix 200mg tablets per day. (Single dose: Day 1, Multiple dose: Day5\ 11)
DRUGPlacebo for Zebinix 400mg
Placebo for Zebinix 400mg group is administered with two placebo for Zebinix 200mg tablets per day. (Single dose: Day 1, Multiple dose: Day5\ 11)
DRUGZebinix 800mg
Zebinix 800mg group is administered with a Zebinix 800mg tablet per day. (Single dose: Day 1, Multiple dose: Day5\ 11)
DRUGPlacebo for Zebinix 800mg
Placebo for Zebinix 800mg group is administered with a placebo for Zebinix 800mg tablets per day. (Single dose: Day 1, Multiple dose: Day5\ 11)
DRUGZebinix 1600mg
Zebinix 1600mg group is administered with two Zebinix 800mg tablets per day. (Single dose: Day 1, Multiple dose: Day5\ 11)
DRUGPlacebo for Zebinix 1600mg
Placebo for Zebinix 1600mg group is administered with two placebo for Zebinix 800mg tablets per day. (Single dose: Day 1, Multiple dose: Day5\ 11)
Sponsors
Whanin Pharmaceutical Company
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
19 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy adult volunteers aged 19-45 years at screening * Subjects who weigh more than 50kg with a body mass index(BMI) of 18.0\ 28.0 kg/m2 at screening * Subjects who are fully understood after being given the detailed explanation of this clinical trial and willing to give written informed consent for participation prior to the screening test * Subjects who are qualified to participate in this clinical trial through the physical examination, clinical laboratory test and interview by the investigators
Exclusion criteria
* Clinically significant presence or treatment history of cardiovascular, hepatic, renal, gastrointestinal, respiratory, neurological, hematological, endocrine, psychiatric * Clinically significant surgical history * Clinically significant family history * Clinically significant atopic syndrome * History of hypersensitivity or clinically significant hypersensitivity to drug including carbamazepine and related compounds * History of alcoholism or drug abuse or show a positive response to an abuse drug in the urine drug screening test * Consistently consume alcohol or cannot stop drinking during the clinical trial * Smoker * Significant infection or inflammatory finding at screening visit * History of gastrointestinal disorders or surgery which may have an effect on the safety and pharmacokinetic evaluation of the investigational products (except for simple appendectomy and herniotomy) * Have used prescription drugs or herbal medication within 2 weeks of initial administration or who have used over the counter(OTC), health functional food or vitamins within 1 week of initial administration (but, if the other conditions are suitable according to the judgment of the investigator, they can participate in the clinical trial), or subjects who have expected to take it * Have participated in any clinical trial (or bioequivalence study) and administered any investigational product within 6 months * Positive for HbsAg, anti-HCV and HIV antigen-antibody reaction tests at screening * Have donated any whole blood or apheresis or received blood transfusion within 3 months of initial administration of this clinical trial * Have dietary restrictions or cannot take the food provided by the institution * Cannot communicate reliably with the investigator * Subjects who are determined by the investigator to be ineligible for participation in this clinical trial due to clinical laboratory test results or other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Metabolic ratio | 'Day 1' 0(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose, 'Day 6~Day 11' 0 hour(pre-dose), 'Day 11' 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose |
| Time of maximum observed drug concentration (Tmax) | 'Day 1' 0(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose, 'Day 6~Day 11' 0 hour(pre-dose), 'Day 11' 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose |
| Maximum observed plasma drug concentration (Cmax) | 'Day 1' 0(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose, 'Day 6~Day 11' 0 hour(pre-dose), 'Day 11' 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose |
| Area under the plasma concentration time-curve (AUC) | 'Day 1' 0(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose, 'Day 6~Day 11' 0 hour(pre-dose), 'Day 11' 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose |
| Apparent terminal elimination half-life (t1/2) | 'Day 1' 0(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose, 'Day 6~Day 11' 0 hour(pre-dose), 'Day 11' 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose |
| Peak trough fluctuation (PTF) | 'Day 1' 0(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose, 'Day 6~Day 11' 0 hour(pre-dose), 'Day 11' 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose |
| Accumulation ratio (R) | 'Day 1' 0(pre-dose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose, 'Day 6~Day 11' 0 hour(pre-dose), 'Day 11' 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96 hour post-dose |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event | Day -1 ~ Day 15 |
Countries
South Korea
Outcome results
None listed